Eone Diagnomics Genome Center Co Ltd - ESG Rating & Company Profile powered by AI
This report of Eone Diagnomics Genome Center Co Ltd was assembled by All Street Sevva using proprietary machine learning. If you are employed by Eone Diagnomics Genome Center Co Ltd and you wish to use your ESG rating, please contact us. Other companies in the rating industry group for Eone Diagnomics Genome Center Co Ltd are shown below.
Eone Diagnomics Genome Center Co Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.5; made up of an environmental score of 0.0, social score of 0.0 and governance score of 1.6.
0.5
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1898 | Zota Health Care Ltd | 0.7 | Low |
1898 | cbdMD Inc | 0.7 | Low |
1924 | Eone Diagnomics Genome Center Co Ltd | 0.5 | Low |
1924 | Beximco Pharmaceuticals Ltd | 0.5 | Low |
1924 | Acucela Inc | 0.5 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Eone Diagnomics Genome Center Co Ltd have an accelerator or VC vehicle to help deliver innovation?
Does Eone Diagnomics Genome Center Co Ltd disclose current and historical energy intensity?
Does Eone Diagnomics Genome Center Co Ltd report the average age of the workforce?
Does Eone Diagnomics Genome Center Co Ltd reference operational or capital allocation in relation to climate change?
Does Eone Diagnomics Genome Center Co Ltd disclose its ethnicity pay gap?
Does Eone Diagnomics Genome Center Co Ltd disclose cybersecurity risks?
Does Eone Diagnomics Genome Center Co Ltd offer flexible work?
Does Eone Diagnomics Genome Center Co Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Eone Diagnomics Genome Center Co Ltd disclose the number of employees in R&D functions?
Does Eone Diagnomics Genome Center Co Ltd conduct supply chain audits?
Does Eone Diagnomics Genome Center Co Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Eone Diagnomics Genome Center Co Ltd conduct 360 degree staff reviews?
Does Eone Diagnomics Genome Center Co Ltd disclose the individual responsible for D&I?
Does Eone Diagnomics Genome Center Co Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Eone Diagnomics Genome Center Co Ltd disclose current and / or historical scope 2 emissions?
Does Eone Diagnomics Genome Center Co Ltd disclose water use targets?
Does Eone Diagnomics Genome Center Co Ltd have careers partnerships with academic institutions?
Did Eone Diagnomics Genome Center Co Ltd have a product recall in the last two years?
Does Eone Diagnomics Genome Center Co Ltd disclose incidents of discrimination?
Does Eone Diagnomics Genome Center Co Ltd allow for Work Councils/Collective Agreements to be formed?
Has Eone Diagnomics Genome Center Co Ltd issued a profit warning in the past 24 months?
Does Eone Diagnomics Genome Center Co Ltd disclose parental leave metrics?
Does Eone Diagnomics Genome Center Co Ltd disclose climate scenario or pathway analysis?
Does Eone Diagnomics Genome Center Co Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Eone Diagnomics Genome Center Co Ltd disclose the pay ratio of women to men?
Does Eone Diagnomics Genome Center Co Ltd support suppliers with sustainability related research and development?
Does Eone Diagnomics Genome Center Co Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Eone Diagnomics Genome Center Co Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Eone Diagnomics Genome Center Co Ltd involved in embryonic stem cell research?
Does Eone Diagnomics Genome Center Co Ltd disclose GHG and Air Emissions intensity?
Does Eone Diagnomics Genome Center Co Ltd disclose its waste policy?
Does Eone Diagnomics Genome Center Co Ltd report according to TCFD requirements?
Does Eone Diagnomics Genome Center Co Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Eone Diagnomics Genome Center Co Ltd disclose energy use targets?
Does Eone Diagnomics Genome Center Co Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Eone Diagnomics Genome Center Co Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for Eone Diagnomics Genome Center Co Ltd
These potential risks are based on the size, segment and geographies of the company.
Eone Diagnomics Genome Center Co., Ltd. provides genetic information analysis services in South Korea. It engages in the genome research and development, genomic testing/screening, IT, and software activities. The company offers NICE, a non-invasive prenatal test, which detects a fetal DNA in maternal plasma for the pregnancy period; bebegene Plus, a newborn genetic screening test that analyzes base sequence and early screening genetic diseases; RiskCARE, which detects the risk of hereditary cancer early to prevent cancer; BRCARE, a genetic test in BRCA1 and BRCA2 genes for hereditary breast/ovarian cancer; genocube, a cancer and general disease prediction test; and Liquid Biopsy, a non-invasive alternative to tissue biopsy that helps to determine cancer treatments by identifying clinically relevant biomarkers. It also provides MYGENPLAN, which suggests personalized health care guide by analyzing personal genetic risks and current health status; TELOAGE that suggests personal genetic risk of diseases and personalized nutrition guide by analyzing current status of telomere; and gene2me Plus, which analyzes genes based on single nucleotide polymorphism array chip and predicts cancers and other diseases, as well as MyEyeGene, a genetic test for inherited eye diseases. Eone Diagnomics Genome Center Co., Ltd. was founded in 2013 and is based in Incheon, South Korea.